NCT06031246 is a Phase 3 clinical trial of Selective Lymph Node Dissection in Lung Adenocarcinoma, sponsored by Fudan University.

Who is sponsoring NCT06031246?

NCT06031246 is sponsored by Fudan University.

What drugs are being tested in NCT06031246?

Interventions in NCT06031246: Selective Lymph Node Dissection.

What condition does NCT06031246 study?

NCT06031246 studies Lung Adenocarcinoma, Lymph Node Metastasis.

Is NCT06031246 still recruiting?

NCT06031246 is currently recruiting now. Last updated 11 September 2023.

Last reviewed 2023-09-11 · How we verify

NCT06031246

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)

Recruiting now Phase 3 Last updated 11 September 2023

What this trial tests

Phase 3 trial testing Selective Lymph Node Dissection in Lung Adenocarcinoma in 634 participants. Currently enrolling.

Timeline

1 April 2023

Primary endpoint
1 January 2026

31 December 2030

Quick facts

Lead sponsor	Fudan University
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	634
Start date	1 April 2023
Primary completion	1 January 2026
Estimated completion	31 December 2030
Sites	1 location across China

Drugs / interventions tested

Selective Lymph Node Dissection

Conditions studied

Lung Adenocarcinoma — all drugs for Lung Adenocarcinoma →
Lymph Node Metastasis — all drugs for Lymph Node Metastasis →

Sponsor

Fudan University

Who can join

Adults 18 to 80, any sex, with Lung Adenocarcinoma or Lymph Node Metastasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1018. The goal of this clinical trial is to confirm the theraputic effect of selective lymph node dissection for cT1N0M0 invasive non-small cell lung cancer with CTR\>0.5 located in the apical segment. The main questions it aims to answer are: The 5-year overall survival of patients having cT1N0M0 invasive non-small cell lung cancer with CTR\>0.5 located in the apical segment; The post-operative lymph node metastasis and recurrence-free survival. Participants will receive selective lymph node dissection as the surgical procedure.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Protocol of a single-arm, multicenter, phase III trial for selective lymph node dissection in cT1N0M0 invasive non-small cell lung cancer with consolidation-tumor ratio >0.5 located in the apical segment: Eastern Cooperative Thoracic Oncology Projects ECTOP-1018 (SELLAS study).
Zhang Y, Deng C, Luo X, Yu Y, et al · · 2024 · PMID 39678839 · DOI 10.21037/jtd-24-1114

Verify or expand the search:

Other recruiting trials for Lung Adenocarcinoma

Currently open trials in the same condition.

NCT07481786 — Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases · Phase 3 · recruiting
NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
NCT07235280 — Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma · EARLY_PHASE1 · recruiting
NCT07161713 — SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors · NA · recruiting
NCT07479095 — Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic · NA · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06031246 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 11 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06031246.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing